This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Morvan syndrome (MoS) is an autoimmune-mediated syndrome that is frequently associated with malignant thymoma and autoantibodies targeting contactin associated protein-like 2 (CASPR2-Abs). Neuropathic pain is a frequent clinical feature in MoS—encountered in 62% of patients1—but the pain mechanisms are unknown. We studied 4 patients with MoS who had neuropathic pain and investigated whether this pain could be due to a selective involvement of small nerve fibers. Written consent was obtained from all patients, and the study was approved by the institutional review board of the University Claude Bernard Lyon 1.
Footnotes
Supplemental data at Neurology.org
Author contributions: Chloé Laurencin: acquisition of data, analysis, interpretation of the data, drafting of the manuscript for intellectual content. Nathalie André-Obadia: analysis and interpretation, critical revision of the manuscript for important intellectual content. Jean-Philippe Camdessanché: acquisition of data, critical revision of the manuscript for important intellectual content. François Mauguière: critical revision of the manuscript for important intellectual content. Elodie Ong: acquisition of data. Sandra Vukusic: critical revision of the manuscript for important intellectual content. Laure Peter-Derex: acquisition of data, critical revision of the manuscript for important intellectual content. François Ducray: acquisition of data, critical revision of the manuscript for important intellectual content. Françoise Bouhour: acquisition of data, critical revision of the manuscript for important intellectual content. Christophe Vial: acquisition of data, critical revision of the manuscript for important intellectual content. David Meyronet: acquisition of data. Jérôme Honnorat: analysis and interpretation, critical revision of the manuscript for important intellectual content, study supervision. Philippe Petiot: analysis, interpretation of the data, drafting of the manuscript for intellectual content, study supervision, study concept and design.
Study funding: No targeted funding reported.
Disclosure: The authors report no disclosures relevant to the manuscript. Go to Neurology.org for full disclosures.
- Received April 6, 2015.
- Accepted in final form August 10, 2015.
- © 2015 American Academy of Neurology
AAN Members: Sign in with your AAN member credentials (e-mail or 6-digit Member ID number)
Non-AAN Member subscribers: Sign in with subscriber credentials
Log in using your username and password
Purchase access
Disputes & Debates: Rapid online correspondence
NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.
- Stay timely. Submit only on articles published within the last 8 weeks.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- 200 words maximum.
- 5 references maximum. Reference 1 must be the article on which you are commenting.
- 5 authors maximum. Exception: replies can include all original authors of the article.
- Submitted comments are subject to editing and editor review prior to posting.